A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum

Status Not yet recruiting

Clinical Trial Summary

The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with severe hepatitis (liver failure). The main questions it aims to answer are: - Mapping of infectious agents in patients with severe hepatitis (liver failure) - Constructing early warning predictive models to explore how to give an individualized regimen of integrated immune function.

Clinical Trial Description

Liver failure is a clinical syndrome caused by a large number of necrotic hepatocytes leading to severe liver function damage, with jaundice, coagulation dysfunction and hepatic encephalopathy as the main manifestations, which can be caused by a variety of reasons, and the liver failure caused by Hepatitis B Virus (HBV) is the first one in our country, which accounts for about 80% of the cases. Through the "Eleventh Five-Year Plan" to "Thirteenth Five-Year Plan" national scientific and technological major special projects, the death rate of patients with early and middle stage of severe hepatitis B has been significantly reduced, but the death rate of patients with advanced stage is still as high as about 60%, especially when liver failure is combined with other complications, such as This study focuses on the impact of secondary infections on the clinical prognosis of severe hepatitis (liver failure), and intends to establish a prospective, multi-center clinical cohort of secondary infections in liver failure, map the infectious pathogens, correlate the basic immune status with the characteristics of the pathogen profile of the secondary infections, and establish a monitoring and early-warning system of secondary infections, so as to explore safe and effective treatment modalities. To further reduce the mortality rate of liver failure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06272071
Study type	Observational
Source	Zhejiang University
Contact	Jiajia Chen
Phone	+8615967109232
Email	Jiajiatale0@zju.edu.cn
Status	Not yet recruiting
Phase
Start date	March 2024
Completion date	November 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03791190` - RCA for CRRT in Liver Failure and High Risk Bleeding Patients	N/A
Recruiting	`NCT05989958` - The Safety and Tolerability Study of HepaCure in Chinese Subjects With Acute-On-Chronic Liver Failure	Phase 1
Completed	`NCT02557724` - Mobilization of Mesenchymal Stem Cells During Liver Transplantation
Recruiting	`NCT01698723` - A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus	Phase 2
Completed	`NCT01404793` - SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation	N/A
Completed	`NCT01425385` - Autoregulation Assessment During Liver Transplantation	N/A
Completed	`NCT03864497` - Myocardial Perfusion Imaging in Liver Transplantation Candidates
Completed	`NCT00808691` - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit	N/A
Completed	`NCT00287235` - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)	N/A
Completed	`NCT03650920` - Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients	N/A
Recruiting	`NCT05517668` - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose	Phase 2
Recruiting	`NCT05726032` - Empagliflozin in Patients With Cirrhosis and Ascites	Phase 2
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting	`NCT02331745` - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure	Phase 4
Not yet recruiting	`NCT01961440` - Prognosis Scoring System for Acute-on-Chronic Liver Failure	N/A
Active, not recruiting	`NCT01221454` - Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure	Phase 2
Completed	`NCT00772148` - Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients	Phase 2
Completed	`NCT05592106` - Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
Not yet recruiting	`NCT06014320` - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
Recruiting	`NCT04221672` - The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of Severe Hepatitis (Liver Failure) Complicated With Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms